Unique ID issued by UMIN | UMIN000053713 |
---|---|
Receipt number | R000061258 |
Scientific Title | Patient and Physician Preferences for Treatment for Hepatitis C Virus Infection in Japan: A Discrete Choice Experiment |
Date of disclosure of the study information | 2024/03/04 |
Last modified on | 2024/02/22 15:07:03 |
Patient and Physician Preferences for Treatment for Hepatitis C Virus Infection in Japan: A Discrete Choice Experiment
Preference Study on Treatment of HCV using DCE
Patient and Physician Preferences for Treatment for Hepatitis C Virus Infection in Japan: A Discrete Choice Experiment
Preference Study on Treatment of HCV using DCE
Japan |
Hepatitis C Virus Infection
Hepato-biliary-pancreatic medicine | Infectious disease | Hepato-biliary-pancreatic surgery |
Others
NO
To elicit specific patient and physician preferences for treatment of HCV, which are important to maintain good adherence and work toward HCV elimination in Japan.
Others
To describe the proportion of each attribute of HCV treatment on the patient and physician perspectives.
Patient and physician preferences regarding HCV treatment.
Shared decision-making process for HCV treatment on patient and physician perspectives.
Observational
18 | years-old | <= |
Not applicable |
Male and Female
Participants must meet all the following inclusion/exclusion criteria.
[Patients]
1)Age 18 and above.
2)Individuals who self-report past or present HCV infection including 1) patients who have received drug therapy for HCV within the past 5 years and 2) patients who have never received any drug therapy for HCV but still presently have HCV.
3)Able to provide informed consent to participate in the study and willing to participate in the study.
[Physicians]
1)At least 3 years of clinical experience, including the period of clinical training.
2)Specializing in gastroenterology or gastroenterological surgery or general internal medicine.
3)Qualified as hepatologists by the Japan Society of Hepatology OR/AND gastroenterologists by the Japanese Society of Gastroenterology.
4)Having treated at least 1 patient with HCV and have prescribed drug therapy for HCV in the past.
5)Able to provide informed consent to participate in the study and willing to participate in the study.
[Patients]
1)Patients with suspected liver cirrhosis.
2)Patients with concomitant carcinoma.
200
1st name | Daisuke |
Middle name | |
Last name | Nakamoto |
Gilead Sciences K.K.
Medical affairs-Liver Diseases Area
100-6616
16F GranTokyo South Tower, 1-9-2 Marunouchi, Chiyoda-ku, Tokyo 100-6616, Japan
03-6837-0055
Daisuke.Nakamoto@gilead.com
1st name | Michael |
Middle name | |
Last name | LOPRESTI |
INTAGE Healthcare Inc.
Value & Access Department
101-0062
13F Ochanomizu SolaCity, 4-6 Kanda-Surugadai, Chiyoda-ku, Tokyo 101-0062, Japan
050-3640-1444
m.lopresti@intage.com
Gilead Sciences K.K.
Gilead Sciences K.K.
Profit organization
Medical Corporation TOUKEIKAI Kitamachi Clinic ERB
1-1-3,Kichijoji-kitamachi,Musashino-shi,Tokyo,180-0001,Japan
03-6779-8116
chi-pr-ec-kitamachi@cmicgroup.com
NO
2024 | Year | 03 | Month | 04 | Day |
Unpublished
Preinitiation
2024 | Year | 02 | Month | 07 | Day |
2024 | Year | 03 | Month | 05 | Day |
2024 | Year | 03 | Month | 11 | Day |
Method: Web-based survey to investigate treatment preferences for HCV patients and physicians.
Utilize discrete choice experiments to measure treatment preferences.
2024 | Year | 02 | Month | 26 | Day |
2024 | Year | 02 | Month | 22 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000061258
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |